Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Malignant gliomas are highly lethal tumors resistant to current therapies. The standard treatment modality for these tumors, surgical resection followed by radiation therapy and concurrent temozolomide, has demonstrated activity, but development of resistance and disease progression is common. Although oncogenic Ras mutations are uncommon in gliomas, Ras has been found to be constitutively activated through the action of upstream signaling pathways, suggesting that farnesyltransferase inhibitors may show activity against these tumors. We now report the in vitro and orthotopic in vivo results of combination therapy using radiation, temozolomide and lonafarnib (SCH66336), an oral farnesyl transferase inhibitor, in a murine model of glioblastoma. We examined the viability, proliferation, farnesylation of H-Ras, and activation of downstream signaling of combination-treated U87 cells in vitro. Lonafarnib alone or in combination with radiation and temozolomide had limited tumor cell cytotoxicity in vitro although it did demonstrate significant inhibition in tumor cell proliferation. In vivo, lonafarnib alone had a modest ability to inhibit orthotopic U87 tumors, radiation and temozolomide demonstrated better inhibition, while significant anti-tumor activity was found with concurrent lonafarnib, radiation, and temozolomide, with the majority of animals demonstrating a decrease in tumor volume. The use of tumor neurospheres derived from freshly resected adult human glioblastoma tissue was relatively resistant to both temozolomide and radiation therapy. Lonafarnib had a significant inhibitory activity against these neurospheres and could potentate the activity of temozolomide and radiation. These data support the continued research of high grade glioma treatment combinations of farnesyl transferase inhibitors, temozolomide, and radiation therapy.
Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Boston, MA, USA.
Deviney
D
Chaponis
Jessica W
JW
Barnes
Jamie L
JL
Dellagatta
Santosh
S
Kesari
Eva
E
Fast
Claire
C
Sauvageot
Dipak
D
Panagrahy
Emily R
ER
Greene
Naren
N
Ramakrishna
Patrick Y
PY
Wen
Andrew L
AL
Kung
Charles
C
Stiles
Mark W
MW
Kieran
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005910:Glioma / Q000628:therapy*; D006801:Humans; D051379:Mice; D009368:Neoplasm Transplantation; D010880:Piperidines / Q000627:therapeutic use*; D054876:Prenylation / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use*; D011839:Radiation, Ionizing; D015398:Signal Transduction / Q000187:drug effects; D000077204:Temozolomide; D013997:Time Factors; D018631:ras Proteins / Q000378:metabolism; D003986:Dibenzocycloheptenes
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D010880:Piperidines; D011725:Pyridines; D000077204:Temozolomide; D018631:ras Proteins; C115354:lonafarnib; D003986:Dibenzocycloheptenes
Neuro Oncol. 2008 Dec;10(6):1004-9
18725460
J Neurooncol. 2005 Jun;73(2):93-100
15981097
Methods Enzymol. 2001;333:284-90
11400344
Oncol Rep. 2004 Feb;11(2):407-14
14719076
Stem Cells. 2009 Apr;27(4):980-7
19353526
Neuro Oncol. 2000 Jul;2(3):151-8
11302335
J Biol Chem. 1995 Nov 10;270(45):26802-6
7592920
Int J Radiat Biol. 1993 Nov;64(5):547-54
7902394
J Clin Oncol. 2002 Mar 1;20(5):1375-82
11870182
EMBO J. 1997 Jul 1;16(13):3877-88
9233798
J Clin Oncol. 2007 Jul 20;25(21):3137-43
17634493
Neurol Res. 2006 Jul;28(5):532-7
16808885
Int J Cancer. 2008 Mar 15;122(6):1236-42
18027853
Oncogene. 1999 Dec 9;18(52):7514-26
10602510
Mol Cancer Ther. 2007 Feb;6(2):773-81
17308073
FASEB J. 2002 Jul;16(9):1126-8
12039842
Neuro Oncol. 2008 Jun;10(3):341-7
18417739
Methods Enzymol. 2001;333:306-18
11400347
Int J Cancer. 2005 May 1;114(5):702-12
15609318
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
14595012
J Clin Oncol. 2006 Jan 20;24(3):507-16
16421428
Oncogene. 2000 Dec 27;19(56):6584-93
11426643
Cancer Res. 2003 Sep 15;63(18):5821-8
14522905
Neurol Clin. 2007 Nov;25(4):891-924, vii
17964020
Neurosurgery. 1999 Dec;45(6):1442-53
10598712
Anticancer Drugs. 2008 Jan;19(1):9-16
18043125
Mol Cell Biol. 2001 Nov;21(21):7429-41
11585923
Radiat Res. 1989 Nov;120(2):267-79
2694214
Neurosurgery. 2006 Feb;58(2):365-72; discussion 365-72
16462491
Am J Pathol. 2007 May;170(5):1445-53
17456751
Neuron. 2007 Feb 15;53(4):503-17
17296553
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
9422557
Angiogenesis. 2008;11(4):337-46
18758974
Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):849-59
2182580
J Cell Biol. 1997 Apr 21;137(2):481-92
9128257
J Biol Chem. 1997 May 30;272(22):14459-64
9162087
Cancer Res. 1998 Apr 15;58(8):1754-61
9563495
Prostate. 2005 Jan 1;62(1):69-82
15389805
Expert Opin Investig Drugs. 2006 Jun;15(6):709-19
16732721
Cancer Res. 2007 Oct 1;67(19):8980-4
17908997
Cancer Res. 2002 Aug 1;62(15):4307-15
12154034
Curr Treat Options Oncol. 2008 Feb;9(1):23-31
18247132
Acta Neuropathol. 2004 Dec;108(6):467-70
15517309
J Biol Chem. 2005 Sep 2;280(35):31101-8
16006564
Neurosurgery. 1999 Nov;45(5):1208-14; discussion 1214-5
10549939
Clin Transl Oncol. 2008 Feb;10(2):73-7
18258505
Cancer Res. 1995 Nov 15;55(22):5302-9
7585592
J Biol Chem. 2003 Feb 21;278(8):6111-9
12486127
Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S23-7
18076314
J Neurochem. 2001 Mar;76(5):1497-508
11238734
Mol Cell Biochem. 2008 May;312(1-2):71-80
18259841